Small molecule inhibitors targeting key pathways

280Bio Inc. is building a drug candidate portfolio of innovative precision small molecule inhibitors targeting key pathways for the treatment of cancers with a significant unmet need. The company is advancing its development programs via a strategic collaboration with MD Anderson Cancer Center and a partnership with Yingli Pharma. 280Bio drug candidates are being developed for monotherapy and combinatorial treatment approaches in solid tumors and hematologic malignancies. 280Bio is preparing for several of these drug candidates to enter the clinic in 2023.

280Bio’s proprietary discovery engine addresses oncology targets with high impact